 | 
 | |
Nile's lead compound, Cenderitide, is a novel rationally designed chimeric natriuretic peptide in clinical studies for an initial indication of acute decompensated heart failure. Nile is also developing CU-NP, a second, novel rationally designed chimeric natriuretic peptide in pre-clinical development.
| |
|
